Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Clinical trial NCT04434040 · RECRUITING
Trial details
- NCT number
- NCT04434040
- Sponsor
- Dana-Farber Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-02
- Primary completion
- 2026-12-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.